October 19, 2010

HELIX BIOPHARMA CORP. RETAINS CFSG1 AS ITS EXCLUSIVE U.S. INVESTOR RELATIONS FIRM (PDF)

AURORA, Ontario, October 19, 2010 – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”), a biopharmaceutical
company focused on cancer therapy, today announced that it has retained Consulting for Strategic Growth 1 (“CFSG1”) as its exclusive U.S. investor relations representative. Stan Wunderlich, Chairman and CEO of CFSG1, and his team will
immediately initiate a proactive investor relations campaign in order to drive investor awareness of Helix’s proprietary
technologies and innovative products for the prevention and treatment of cancer.